Research digest · Dose & pharmacology
MOTS-c peptide dosage and pharmacology, as the research literature actually reports them.
The rodent regimens studied, the routes used, the absence of a validated human half-life, and the safety context — described, never prescribed.
The short version
Every MOTS-c peptide dose in the published record comes from animal studies. Researchers gave mice roughly half a milligram to fifteen milligrams per kilogram of body weight, usually as a shot into the abdominal cavity, dosed daily or three times a week over several weeks. There is no established human dose, no measured human half-life, and no approved product. Reading the animal numbers as a human protocol is exactly what the science does not support. This page reports what was administered to which species, and nothing more.
MOTS-c Dosage in the Research Literature
MOTS-c dosage in the research literature is reported entirely in animal terms. In the founding 2015 metabolic work, mice received roughly 0.5 mg/kg/day intraperitoneally (IP) for chronic studies of about 8 weeks, and 5 mg/kg/day IP for a shorter 7-day acute protocol [1]. In the 2021 aged-mouse physical-capacity study, the regimen was 15 mg/kg/day IP, or 15 mg/kg IP three times per week [2]. Bone-metabolism work summarized in review has used 5 mg/kg/day IP over 12 weeks [9].
These figures are studied doses in mice, expressed per kilogram of body weight. They are not human-equivalent doses; rodent milligram-per-kilogram values do not translate directly to people, and no conversion has been clinically validated [4]. The correct reading of this section is descriptive: it tells you what experiments administered, not what any person should take.
Notice the range itself — 0.5 to 15 mg/kg/day is a thirty-fold spread, and it tracks the question being asked. The lower end (0.5 mg/kg/day) appears in chronic metabolic studies aimed at insulin sensitivity and body weight [1]; the higher end (15 mg/kg/day, or 15 mg/kg three times weekly) appears in the aged-mouse physical-capacity work [2]. Different endpoints, different regimens. That variability is one more reason the animal literature does not hand over a single "dose" to carry across to humans: even within mice, the amount given depended on what the experiment was measuring.
MOTS-c Half-Life and Pharmacokinetics
No validated human pharmacokinetic half-life has been published for MOTS-c. As a small, unmodified peptide, native MOTS-c is expected to be short-lived in circulation, and published in-vivo work relies on repeated daily or thrice-weekly dosing rather than a measured human t½ [1][2]. The dosing schedules themselves are the clearest evidence of this: when a compound is given daily or three times weekly to maintain an effect [2], that pattern implies rapid clearance rather than a long-lived depot. To improve delivery, cell-penetrating analogues have been engineered in certain studies — a research strategy to get more of the peptide into tissue, not a marketed formulation [4].
How Long Does MOTS-c Stay in Your System?
No validated human pharmacokinetic half-life has been published. As a small unmodified peptide it is expected to be short-lived in circulation, which is why published in-vivo work relies on repeated daily or thrice-weekly dosing rather than a single measured human clearance time [1][2].
How MOTS-c Is Administered in Research
How MOTS-c Is Administered in Research
The dominant route in rodent studies is intraperitoneal (IP) injection — directly into the abdominal cavity, a standard laboratory route in mice that is not a human clinical route [1][2]. Subcutaneous injection has also been used in research contexts, cell-culture work covers the in-vitro studies, and cell-penetrating analogues have been given peripherally in a neuroprotection study [4].
MOTS-c is supplied for laboratory use as a lyophilized (freeze-dried) powder; reconstitution and storage conditions are vendor- and study-specific, and no standardized human formulation exists [4]. Because the research routes (especially IP injection in mice) and the research doses are laboratory parameters, this digest describes them without translating them into any human administration instruction.
MOTS-c Side Effects and Safety Context in Studies
The honest statement about MOTS-c side effects is that there is no completed human safety trial to draw a profile from. There are no completed interventional human efficacy or safety trials of exogenous MOTS-c; the human evidence base is observational and biomarker-level [14]. A safety profile cannot responsibly be asserted — not because the peptide has been shown safe, but because the controlled human studies that would characterize tolerability and adverse effects have not been done.
Several further cautions belong here. Rodent doses (0.5–15 mg/kg/day) cannot be extrapolated to humans, and the gap between a mouse milligram-per-kilogram figure and a human one is not a simple multiplier [1][2]. As a research chemical, MOTS-c purity, identity, and sterility vary by supplier and are not regulated as pharmaceuticals — the molecule in a research vial is not held to the manufacturing standards of an approved drug. Effects may not be uniform across people, either: a pro-diabetogenic mtDNA variant (m.1382A>C) and ancestry-dependent exercise responses suggest genotype matters, so a finding in one population is not automatically a finding in another [7]. And in elite sport, MOTS-c is treated as a prohibited substance — see the MOTS-c legal status and 503A category page for the regulatory and anti-doping detail.